News | October 08, 2009

Philips to Apply Digital Silicon Photomultipliers to Medical Imaging

October 8, 2009 - Royal Philips Electronics said it has developed a digital silicon photomultiplier technology that will allow faster and more accurate photon (the basic quantum unit of light) counting in a wide range of applications where ultra-low light levels need to be measured.

Areas where the new technology could have a major impact include medical imaging, in particular positron emission tomography (PET), and in-vitro diagnostic tests such as DNA sequencing and protein/DNA microarrays. Other relevant areas include high-energy physics, night-vision systems and other applications that currently use light detectors that are based on so-called photomultiplier tubes.

As with virtually all ‘solid-state’ alternatives, this new digital silicon photomultiplier technology should enable the production of smaller and lighter battery-powered equipment for use in areas such as medical diagnostics and surveillance. The key to the technology lies in its ability to combine high-quality single-photon detectors (silicon avalanche photodiodes) with low-voltage CMOS logic on the same silicon substrate. Moreover, these new silicon photomultipliers can be manufactured using a conventional CMOS process technology.

The performance of Philips’ prototype detector, in terms of its speed and dark count level (background noise), will be presented at the IEEE Nuclear Science Symposium and Medical Imaging Conference, which will take place on October 25-31 in Orlando, Fla. Other important features of this new light detection technology include its robustness, low power consumption, light detection efficiency, and very high level of integration of the optical detection and associated electronic components.

“Solid-state digital technology has already taken over from outdated analog solutions in every-day applications such as TVs, camcorders and photography,” says Rob Ballizany, vice president of Philips Corporate Technologies and responsible for the commercialization of this new technology. “...high-end professional applications such as medical imaging will undergo a similar switch to digital detectors in the next few years.”

For more information: www.medical.philips.com

Related Content

Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
PET, PET imaging, PET-CT, FDG PET, PET cancer assessment, pet scanner, nuclear imaging, molecular imaging

A PET-CT head and neck cancer scan showing various image reconstructions. The top left image is the separate CT scan showing the anatomy. The top right scan shows the fused PET and CT scans with false color added to help interpret the image. The bottom left scan is an initial FDG PET image showing tracer hot spots in the neck and a lymph node in the right jaw due to cancer. The right bottom image is a delayed enhancement scan showing tracer uptake over time, with normal hot spots in the bladder, kidneys, testicles and brain, which normally have higher metabolic activity. The low-grade gray shading of the anatomy is due to the normal cellular metabolism uptake of the FDG throughout the body. 

News | PET-CT | August 04, 2021
August 4, 2021 — PET/CT systems are exp

Image courtesy of Vital Images

News | Molecular Imaging | August 02, 2021
August 2, 2021 — The global molecular imaging marke
Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly and Annual Meeting, the world’s largest annual radiology forum, to be held at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | July 21, 2021
July 21, 2021 — Registration is now open for the Radiological Society of North America (...
A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high sensitivity that supports excellent spatial resolution and image quality. Given the long axial field of view (AFOV) of the uEXPLORER, study authors have proposed new, extended measurements for phantoms to characterize total-body PET imaging more appropriately. This research was published in the June issue of The Journal of Nuclear Medicine.

Human imaging examples of performance of uEXPLORER total-body PET scanner. (A) Axial slice from 18F-fluciclovine PET image (right), with corresponding fused image (middle) and CT image (left), of 68-y-old patient with castration-resistant metastatic prostate cancer, demonstrating clear visualization of 18F-flucicovine accumulation within 2.5-mm-diameter pulmonary nodule. (B) Maximum-intensity projection of representative clinical oncology 18F-FDG PET scan reconstructed with 20-, 5-, and 2.5-min durations, of 59-y-old patient with lung cancer. Images show primary tumor in left lower lobe of lung (dashed circle), with multiple variable-sized (0.8-6 cm) hilar, mediastinal, and lower esophageal nodal metastases (arrows) and ~1-cm 18FFDG-avid left adrenal nodule (arrowhead), which is visualized for all scan durations. Image created by Y. Abdelhafez and B.A. Spencer, EXPLORER Molecular Imaging Center, UC Davis, Sacramento, CA

News | PET Imaging | July 10, 2021
July 10, 2021 — A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-hig
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.

Figure 1. Case example: A 54-year-old man with a history of RP+LND and a subsequent PSA of 1.25 ng/mL had no evidence of disease by baseline imaging. Piflufolastat F 18 (18F-DCFPyL)- PET/CT accurately detected biochemically recurrent prostate cancer with the PSMA PET/CT scan identifying positive left (left panel) and right peri-rectal lymph nodes (right panel).

News | Prostate Cancer | June 21, 2021
June 21, 2021 — A phase III clinica...